Alligator Bioscience Executives Back TO 14 Warrant Exercise, Potentially Raising SEK 49 Million

Alligator Bioscience AB ( (SE:ATORX) ) has provided an update.

Alligator Bioscience’s CEO Søren Bregenholt and CFO Johan Giléus plan to subscribe for their full pro rata portions in the company’s ongoing TO 14 warrant exercise, signaling management’s confidence in the business and its pipeline. The TO 14 warrants, issued as part of a 2025 rights issue, carry a subscription price of SEK 0.20 and could raise about SEK 49 million before costs if fully exercised, providing important funding capacity for the company’s late-stage oncology programs and reinforcing investor focus on its capital structure and growth plans.

The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.

More about Alligator Bioscience AB

Alligator Bioscience AB is a Swedish biotechnology company developing clinical-stage, tumor-directed antibody drugs, with a focus on the CD40 receptor in immuno-oncology. Its lead candidate, mitazalimab, is ready for Phase 3 development and has shown strong 30‑month survival data in a Phase 2 trial in metastatic pancreatic cancer, positioning the firm as an emerging player in advanced cancer immunotherapies.

YTD Price Performance: -41.07%

Average Trading Volume: 5,223,216

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK105.8M

For detailed information about ATORX stock, go to TipRanks’ Stock Analysis page.